<DOC>
	<DOC>NCT02013271</DOC>
	<brief_summary>To demonstrate efficacy and safety of the Lutonix® Drug Coated Balloon for treatment of long TASC II Class C and D lesions (≥ 14 cm) lesions in the SFA</brief_summary>
	<brief_title>Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Clinical Criteria 1. ≥ 18 years of age; 2. Rutherford Clinical Category 24; 3. Subject is legally competent and voluntarily agrees to participation and the study's provisions; is willing to provide 5year informed consent; 4. ≥ 70% stenosis of a native femoropopliteal artery (by visual estimate) that is amenable to DCB with or without stenting; 5. TASC II Class C or D Lesions with intended target lesion treatment segment(s) cumulatively ≥14 cm in length; 6. de novo lesion(s) or nonstented restenotic lesion(s) &gt; 90 days from prior angioplasty procedure; 7. Target vessel diameter between ≥ 4 and ≤ 7 mm; 8. Successful wire crossing of lesion and predilatation; 9. No other prior vascular interventions (including contralateral limb) within 2 weeks before and/or planned 30 days after the protocol treatment. 1. Women who are pregnant, lactating, or planning on becoming pregnant or men intending to father children; 2. Patient is contraindicated to use Lutonix Drug Coated Balloon per the current Instructions For Use (IFU); 3. Life expectancy of &lt; 1year; 4. Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; 5. History of stroke within 3 months; 6. History of myocardial infarction, thrombolysis or angina within 2 weeks of enrollment; 7. Prior vascular surgery of index limb with exception of endarterectomy or remote common femoral patch angioplasty; 8. Target lesion involves a previously placed stent; 9. Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre and postprocedure medication; 10. Significant inflow disease; 11. Known inadequate distal outflow or planned future treatment of vascular disease; 12. Sudden symptom onset, acute vessel occlusion, or acute or subacute angiographically visible thrombus in target vessel; 13. Use of adjunctive treatment modalities (e.g. laser, atherectomy or cryoplasty)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>